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Background: Pol III-related leukodystrophies, including 4H leukodystrophy, are recently recognized disorders that
comprise hypomyelination and various neurologic and non-neurologic clinical manifestations. We report the unique
neurologic presentation of the micturition dysfunction in Pol III-related leukodystrophy and describe the novel
endocrine abnormalities in this entity.
Case presentation: A 32-year-old Caucasian female exhibited chronic urinary incontinence that commenced at the
age of 7 years and remained the unexplained symptom more than two decades before the onset of progressive
neurologic decline. A transient growth failure and absent sexual development with hypoprolactinemia appeared in
the meanwhile. Neurologic, endocrine, neuroradiologic, and genetic evaluation performed only in the patient’s
thirties, confirmed the diagnosis of 4H leukodystrophy as the only cause of the micturition disturbance.
Conclusion: The report shows for the first time that an unexplained chronic bladder dysfunction should be
evaluated also as a possible 4H leukodystrophy, thus alerting to the unexpected neurologic and endocrine features
in 4H leukodystrophy.
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4H leukodystrophy is a rare disorder that includes
hypomyelination, hypogonadotropic hypogonadism and
dental developmental anomalies [1]. It belongs to a
spectrum of clinically and radiologically overlapping
diseases caused by recessive mutations in either POLR3A
or POLR3B, and collectively designated as “Pol III-
related leukodystrophies” [1]. Despite the diversity of
neurologic manifestations observed in these entities [1],
little is known about sphincter dysfunctions and endo-
crine features [1]. Impairment of bladder/bowel function
may be a part of the clinical picture of leukodystrophies.
However, with only few exceptions among adult-onset
leukodystrophies, it is neither a prominent nor an early
feature of the disease, but rather appears in the advanced
stages. According to the current knowledge on Pol III-
related leukodystrophies, such evolution of the symptoms* Correspondence: a.potic@yahoo.com
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unless otherwise stated.seems to be the characteristic of these rare diseases as
well. Therefore, the childhood-onset neurogenic bladder
persisting for decades as the only neurologic manifestation
of Pol III-related leukodystrophy represents a noteworthy,
so far unique phenomenon. The data on the accompany-
ing endocrine features are still incomplete in a large num-
ber of patients with Pol III-related leukodystrophy due to
the deficient endocrine evaluation in this disorder. Apart
from the variable observations on the growth hormone
deficiency provided in some [2], the main attention has
been given to hypogonadotropic hypogonadism in most of
these patients. The report broadens the endocrine mani-
festations in 4H leukodystrophy with regards to the pro-
lactin deficiency and suggests establishing the endocrine
protocol for Pol III-related leukodystrophy.
Case presentation
The patient was a 32-year-old Caucasian female, the
third-born to healthy non-consanguineous parents with
negative family history of neurologic disorders. The
pregnancy, birth and early psychomotor development
were uneventful. At the age of 7 years chronic urinaryhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical abnormality for 20 years. Prompt nephrologic,
gynecologic, and urologic investigations (also including
voiding cystourethrogram, cystoscopy, renal scintig-
raphy, ultrasonography, biochemical analyses of blood
and urine) were normal, and there were no accompany-
ing neurologic signs in the overall clinical status. The
persisting urinary disturbance brought the patient to
neurologic attention only at 32 years of age when the as-
sessment disclosed a 5-year history of slowly progressive
cerebellar ataxia followed by pyramidal signs, and then
focal upper extremity dystonia. The neuropsychological
evaluation at the age of 32 years documented a mild in-
tellectual disability for the first time (full-scale IQ of 57;
Wechsler Adult Intelligence Scale-IV). It was thought to
be a decline compared to the patient’s historical level of
functioning: the patient had finished the compulsory
education (age 7–15 years) with regular psychological
assessments, was employed as a factory worker, and was
able to live independently. She stopped working at the
age of 32 years during the neurologic follow-ups. Mag-
netic resonance imaging (MRI) of the brain revealed
diffuse supratentorial hypomyelination that bilaterally
spread along the posterior limb of the internal capsule
affecting the pyramidal tracts, the middle and inferior
cerebellar peduncles (Figure 1a, b, c). T2-weighted
hypointensities were observed in the globi pallidi, the
optic radiations and the dentate nuclei (Figure 1b, d).Figure 1 Magnetic resonance imaging (MRI) study in the patient with
indicating hypomyelination; (b) T2W (T2-weighted) scan of the brain and
cerebellar peduncles:T2W scan; (d) T2W-hypointensity of the nucleus den
the adenohypophisis: sagittal T1W scan; (f) the small adenohypophysis: c
decreased choline/creatine ratio in the lesions; (h) Diffusion tensor imagi
spinal cord: T2W scans.There was a marked atrophy of the cerebellum and
corpus callosum, as well as of the pontine and midbrain
tegmentum (Figure 1e). The adenohypophysis was small
(Figure 1e, f ). Multivoxel MR Spectroscopy of the brain
detected a markedly decreased choline/creatine ratio in
the abnormal white matter (Figure 1g). Diffusion tensor
imaging of the brain showed a slightly reduced fractional
anisotropy consistent with hypomyelination (Figure 1h).
MRI of the brain pointed to Pol III-related leukodystro-
phy [3]. MRI of the spinal cord was normal (Figure 1i, j).
Electromyoneurography was unremarkable. Urodynamic
tests (uroflow study, postvoid residual volume, filling-
voiding cystometry, abdominal leak-point pressure, exter-
nal sphincter electromyography-EMG) revealed decreased
bladder capacity with preserved sensation, uninhibited
detrusor muscle contractions, and detrusor- external
sphincter synergy, while sphincter EMG recorded normal
amplitudes and duration of muscle potentials. The urody-
namic study proved the bladder overactivity due to neu-
rologic, suprapontine lesion [4]. The repeated urologic,
nephrologic, and metabolic investigations remained normal.
At 26 years of age the patient had no sexual development
(Tanner stage 1, primary amenorrhea). Hypogonadotropic
hypogonadism, low baseline prolactin level and growth hor-
mone (GH) deficiency were confirmed (Table 1). Her
height was below the 3rd percentile and she was normos-
mic. The karyotype was normal. The patient received
sexual hormone replacement for 3 years. At 32 years of age4H leukodystrophy. (a) T1W (T1-weighted) axial scan of the brain
T2W-hypointensity of the globi pallidi; (c) affection of the middle
tatus; (e) atrophy of the cerebellum, brainstem, corpus callosum and
oronal T1W scan + contrast; (g) Magnetic resonance spectroscopy:
ng of the brain supporting hypomyelination; (i, j) the unaffected
Table 1 Endocrine evaluation in the patient with 4H
leukodystrophy






FSH (IU/L) 1.1 1.4 2.5-15
Peak FSH after LHRH
test (IU/L)
1.5 1.5 >5
LH (IU/L)a <1.0 1.1 4-20
Peak LH after LHRH test
(IU/L)
<1.0 1.3 >5




Peak prolactin after ITT
(ng/mL)c
4.7 4.5 >> > b
Peak prolactin after TRH
test (ng/mL)d
N/A 6 >> > b
Thyroxine (nmol/L) 134.7 N/A 60-170







TSH (mIU/L) 1.0 1.7 0.15-5.0
Cortisol (nmol/L) 332 428 131-642
Peak cortisol after ITT
(nmol/L)c
922 827 >550




Peak GH after ITT (μg/L)c 2.4 6.1 >3
Abbreviations: FSH, follicle-stimulating hormone; LHRH, luteinizing hormone-
releasing hormone; LH, luteinizing hormone; ITT, insulin tolerance test; TRH,
thyrotropin-releasing hormone; IGF-1, insulin-like growth factor 1; GH,
growth hormone.
aLH measured every 15 minutes during 8 hours; bMean of three diurnal values
measured at 08 h-11 h-13 h; cAfter insulin tolerance test; dAfter TRH test;
eThree diurnal values measured at 08 h-11 h-13 h; >> > b: Several-fold increase
compared to the mean daily prolactin.
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sence of luteinizing hormone pulsatility (Table 1). Hypopro-
lactinemia was confirmed by two stimulatory tests (insulin
tolerance test-ITTand thyrotropin-releasing hormone-TRH
test), while growth hormone level was normal (Table 1).
Other hormonal values were normal (Table 1). Her final
adult height was 155 cm (10th percentile) and Tanner stage
was 4, with amenorrhea. Given the accompanied hypoes-
trogenemia, gynecologic and urogynecologic examinations
excluded atrophic vaginitis, vulvar structural anomalies,
and decreased strength of the pelvic floor and bladder mus-
cles, as possible estrogen-related causes of the urinary in-
continence [5]. Dental examination confirmed hypodontia
with the lack of second and third molars. A genetic evalu-
ation was necessitated: sequencing of the key exons andexon-intron boundaries of POLR3A using previously
reported methods [6], revealed two already known disease-
causing mutations, c.272C >T (p.P91L) in exon 3 and
c.3014G >A (p.R1005H) in exon 23 which segregated in
the parents and proved the diagnosis of 4H leukodystrophy.
Discussion
The neurologic, endocrine, metabolic, neuroradiologic, and
genetic investigations confirmed 4H leukodystrophy in the
reported patient and ruled out possibility of any neurologic
comorbidity. After excluding all non-neurologic causes of
the chronic urinary incontinence [5,7] and having proven
the neurogenic origin of the bladder dysfunction by the
urodynamic studies [4], we concluded that the isolated
micturition dysfunction had been the first and sole neuro-
logic manifestation of the unrecognized 4H leukodystrophy
for over two decades. Such a long lag between the onset of
the neurogenic bladder and the subsequent neurologic
symptom has not been described in Pol III-related leuko-
dystrophy, or in any other leukodystrophies [8]. The sites
responsible for the bladder dysfunction in this report seem
to be the affected suprapontine brainstem tegmentum,
basal ganglia, and cerebellum, along with their central
afferent-efferent circuitry. Furthermore, the patient pre-
sented hypogonadotropic hypogonadism which was add-
itionally accompanied by hypoprolactinemia and transient
growth hormone deficiency. The hypoestrogenic state de-
fined by hypogonadotropic hypogonadism was not proven
to have caused urinary incontinence in this case, but such
possibility should be considered in female patients with 4H
leukodystrophy. The transient GH deficiency is thought to
be due to lack of sex steroid priming of somatotrophs and
is a novel variant of growth hormone deficiency reported
in this disorder. Prolactin deficiency in 4H leukodystrophy
is an intriguing observation which cannot be explained by
any currently known causes of hypoprolactinemia [9]. It
has been reported only in two other patients with Pol
III-related leukodystrophy: originally in our first patient in
2012 [2], and recently in a Japanese patient [10]. POLR3A
mutations have been found in these three patients. The
study by Wolf et al. suggested that patients with POLR3A
had, in general, more severe disease than patients with
POLR3B mutations, despite the fact that disease onset was
slightly earlier in the latter group [11]. This was reflected
in both age at loss of supported walking and survival [11].
The role of POLR3A and POLR3B in the endocrine distur-
bances and the pathogenesis of these disorders still wait to
be elucidated by future research [12].
Conclusions
This is the first report providing the evidence that the
myelin affection in a hypomyelinating leukodystrophy
may neurologically manifest as a single symptom lasting
for decades before the next neurologic decline. The fact
Potic et al. BMC Neurology  (2015) 15:22 Page 4 of 4that such a neurologic symptom can be the childhood-
onset chronic urinary incontinence represents another
novelty verified in the observed hypomyelinating process.
The study also illustrates the complexity of the endocrine
features and broadens the phenotype in Pol III-related
leukodystrophy.
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